Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Endpoints in lung cancer trials: today’s challenges for clinical statistics

Endpoints in lung cancer trials: today’s challenges for clinical statistics The identification of potential molecular targets in lung cancer has stimulated the today’s search for antitumor agents to be tested in clinical trials with an appropriate endpoint. Three main categories of classical endpoints are applied: survival time endpoints, symptom endpoints, and endpoints relying on patients’ reporting, with the gold standard overall survival (OS). Efforts have been taken to substitute OS by surrogates. As a surrogate for OS, progression-free survival (PFS) should have the inherent considerable advantage, that it can detect subpopulations with longer PFS intervals early. OS and PFS was linked directly by splitting OS into PFS and the rest as survival time past progression (SPP). Variation in SPP is a quantitative factor in validating PFS as a surrogate of OS. If accompanied by some independent measures like quality of life (QoL) or treatment toxicity, PFS should be able to cover the clinical benefit achieved by treatment. In an adaptive trial design, the impact of SPP can be modeled by adjustments of the covariate structure by factors as QoL. OS as the gold standard is easy to measure and is precise but results are available late. PFS in contrast is complex to measure but will become attractive, because its results are available earlier and are not influenced by subsequent therapies. Therefore, PFS, as an endpoint with some extra measures, has become an acceptable alternative to OS in lung cancer trials recently. Extra measures under discussion to enrich PFS are QoL and information of SPP, or adaptive designs. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Endpoints in lung cancer trials: today’s challenges for clinical statistics

Download PDF
6 pages

Loading next page...
 
/lp/springer-journals/endpoints-in-lung-cancer-trials-today-s-challenges-for-clinical-57RS4MfnN8
Publisher
Springer Journals
Copyright
Copyright © 2013 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-013-0082-z
Publisher site
See Article on Publisher Site

Abstract

The identification of potential molecular targets in lung cancer has stimulated the today’s search for antitumor agents to be tested in clinical trials with an appropriate endpoint. Three main categories of classical endpoints are applied: survival time endpoints, symptom endpoints, and endpoints relying on patients’ reporting, with the gold standard overall survival (OS). Efforts have been taken to substitute OS by surrogates. As a surrogate for OS, progression-free survival (PFS) should have the inherent considerable advantage, that it can detect subpopulations with longer PFS intervals early. OS and PFS was linked directly by splitting OS into PFS and the rest as survival time past progression (SPP). Variation in SPP is a quantitative factor in validating PFS as a surrogate of OS. If accompanied by some independent measures like quality of life (QoL) or treatment toxicity, PFS should be able to cover the clinical benefit achieved by treatment. In an adaptive trial design, the impact of SPP can be modeled by adjustments of the covariate structure by factors as QoL. OS as the gold standard is easy to measure and is precise but results are available late. PFS in contrast is complex to measure but will become attractive, because its results are available earlier and are not influenced by subsequent therapies. Therefore, PFS, as an endpoint with some extra measures, has become an acceptable alternative to OS in lung cancer trials recently. Extra measures under discussion to enrich PFS are QoL and information of SPP, or adaptive designs.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: May 8, 2013

References

  • Schmid-Bindert G. Statistical considerations and endpoints for clinical lung cancer studies: can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small cell lung cancer?
    Pilz, LR; Manegold, C
  • Techniques for censored and truncated data.
    Klein, PJ; Moeschberger, ML. Survival analysis.
  • Randomization in clinical trials: Theory and practice
    Rosenberger, WF; Lachin, JM.
  • Statistics notes: blinding in clinical trials and other studies
    Day, SJ; Altman, DG
  • Blinding in randomized trials: hiding who got what
    Schulz, KF; Grimes, DA
  • Evaluation of disease-free survival as surrogate endpoint for overall survival using two individual patient data meta-analyses of adjuvant chemotherapy in operable non-small cell lung cancer
    Michiels, S; Mauguen, A; Fisher, D
  • Response rate as an endpoint in clinical trials. Editorial
    George, SL
  • Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy
    Thongprasert, S; Sanguanmitra, P; Juthapan, W; Clinch, J
  • Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis
    Johnson, KR; Ringland, C; Stokes, BJ
  • Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?
    Soria, JC; Massard, C; Le, T.
  • Comparing two failure time distributions in the presence of dependent censoring
    Lin, DY; Robins, JM; Wei, LJ
  • Investigation of disease-free survival as a surrogate endpoint for survival in cancer clinical trials
    Chen, TT; Simon, RM; Korn, EL
  • Primary endpoints in cancer trials
    Ulm, K
  • Detecting an overall survival benefit that is derived from progression free survival
    Broglio, KR; Berry, DA
  • The relationship between progression free and post-progression survival in treating four types of metastatic cancer
    Bowater, RJ; Bridge, LJ; Lilford, RJ
  • Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for non-squamous non-small cell lung cancer: results from a randomized phase III trial (AVAiL)
    Reck, M; von Pawel, J; Zatloukal, P
  • Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer
    Hotta, K; Suzuki, E; Di Maio, M
  • Post-study therapy as a source of confounding in survival analysis of first-line studies in patients with advanced non-small-cell lung cancer
    Zietemann, VD; Schuster, T; Duell, THG
  • Expertenempfehlung 2006 zur rationalen Zweitlinien-Therapie beim nicht-kleinzelligen Bronchuskarzinom
    Hilbe, W; Aigner, K; Dittrich, C
  • Issues in using progression-free survival when evaluating oncology products
    Fleming, TR; Rothmann, MD; Lu, H-L
  • End points and United Stated Food and Drug Administration approval of oncology drugs.
    Johnson, JR; Williams, G; Pazdur, R
  • Surrogate end points in clinical trials: Are we being misled?
    Fleming, TR; DeMets, DL
  • Role of survival post-progression in Phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review
    Hotta, K; Kiura, K; Fujiwara, Y
  • Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer
    Hayashi, H; Okamoto, I; Morita, S; Taguri, M; Nakagawa, K
  • Quality of life as endpoint of clinical trials
    Reck, M
  • Surrogate end points of quality of life assessment: have we really found what we are looking for?
    Tassinari, D.
  • Composite and surrogate outcomes in randomized controlled trials. Editorial
    Freemantle, N; Calvert, M.
  • Design of clinical studies: adaptive randomization and progression-free survival (PFS) as an endpoint in clinical studies of advanced non-small cell lung cancer (NSCLC).
    Schrimpf, D; Manegold, C; Pilz, LR